Episode 12: Tinder for T Cells - Bispecifics in DLBCL
About this episode
In this episode, we are joined by two lymphoma experts - Victoria Nachar, PharmD, BCOP and Tycel Phillips MD - to discuss the use of bispecific antibodies in Diffuse Large B-Cell Lymphoma (DLBCL)! Stay tuned for an exciting episode where we discuss the data, their possible role in therapy, and what questions and controversies remain.
Relevant Articles:
Review on Design of Bispecifics - https://pubmed.ncbi.nlm.nih.gov/25728220/
Epcoritamab - https://pubmed.ncbi.nlm.nih.gov/36548927/
Glofitamab - https://pubmed.ncbi.nlm.nih.gov/36507690/
Mosunetuzumab - https://pubmed.ncbi.nlm.nih.gov/34914545/
Odronextamab - https://pubmed.ncbi.nlm.nih.gov/35366963/
CRS and ICANS grading - https://pubmed.ncbi.nlm.nih.gov/30592986/
Get every episode summarized
Each time WolverHeme Happy Hour publishes, we email you a written briefing from the transcript — the topics, who appeared, and any specific claims, with the ad reads skipped.
Email me new episodesFree for 3 shows. No card needed.
Hosts & guests
No transcript yet
This episode has not been transcribed. Request it and it moves to the front of the queue.
More episodes
More from WolverHeme Happy Hour
VAR Review with Dr. Bixby: Reversing the Call on MPAL
WolverHeme Happy Hour
Bispecifics ate CAR-T's lunch: a multiple myeloma debate
WolverHeme Happy Hour
Episode 47: Cult-Like Thinking in BMT
WolverHeme Happy Hour
Spring Cleaning the Evidence from ASH 2025 with Common Sense Oncology
WolverHeme Happy Hour